Regencell Bioscience Holdings Limited
RGC
$12.80
$0.241.91%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.78M | 4.17M | 4.55M | 4.68M | 4.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.74M | 4.95M | 5.16M | 5.71M | 6.27M |
| Operating Income | -4.74M | -4.95M | -5.16M | -5.71M | -6.27M |
| Income Before Tax | -4.36M | -4.65M | -4.93M | -5.50M | -6.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.36 | -4.65 | -4.93 | -5.50 | -6.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 61.40K | 142.00K | 222.60K | 206.90K | 191.20K |
| Net Income | -4.30M | -4.51M | -4.71M | -5.29M | -5.87M |
| EBIT | -4.74M | -4.95M | -5.16M | -5.71M | -6.27M |
| EBITDA | -4.44M | -4.65M | -4.90M | -5.49M | -6.09M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Average Diluted Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |